Interventional Imaging
Stage
Other Investors | DeadAbout Interventional Imaging
Interventional Imaging Inc. (I3) is a medical device company focused on the detection and treatment of vulnerable plaque in the coronary arteries of the heart. I3 was formed by Case Western Reserve University and is based on technologies developed in the Department of Radiology at University Hospitals of Cleveland.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Latest Interventional Imaging News
Aug 16, 2023
News provided by Share this article Share toX The global tumor ablation market size is expected to reach USD 4.07 billion by 2030 and is expected to expand at a CAGR of 13.6% from 2023 to 2030 The increasing incidence of cancer and the high demand for effective treatment options are the major factors driving the market. According to Cancer Research UK, the incidence rate of cancer is expected to grow by 62% from 2018 to 2040. Lung, breast, bowel, and prostate are the most common sites reported with cancer in 2018. Increasing inclination towards minimally invasive procedures owing to the benefits such as speedy recovery, patient comfort, and shorter turnaround time are the factors expected to foster the demand for advanced tumor ablation techniques during the forecast period. The integration of tumor ablation devices with efficient interventional imaging modalities such as ultrasound, MRI, and CT is anticipated to revolutionize ablation procedures performed in outpatient settings. This is expected to significantly eliminate the cost to the patient including hospital stays. Supportive government initiatives such as screening programs, awareness campaigns, and cancer schemes for various cancer types are expected to increase the number of diagnosed cases. For instance, in 2019, the National Health Scheme (NHS) started offering lung cancer screening programs in some areas of England. Such initiatives are anticipated to escalate the need for cancer management in early cancer stages, thereby facilitating the demand for tumor ablation therapy. The rising demand for advanced medical technologies, coupled with improving financing capabilities of healthcare facilities, is expected to increase the demand for tumor ablation devices during the forecast period. Tumor Ablation Market Report Highlights The radiofrequency ablation technology segment dominated the market with more than 35.0% share in 2022 owing to its prominent application in solid tumor removal By treatment, percutaneous ablation is expected to witness lucrative growth over the forecast period due to the rising demand for minimally invasive procedures offering faster recovery and higher safety Tumor ablation in lung cancer treatment is anticipated to witness the fastest growth over the forecast period A sedentary lifestyle, increasing incidences of smoking, and rising air pollution are contributing to the growing prevalence of lung cancer North America dominated the market in 2022 owing to the factors such as the increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and the availability of reimbursement Companies Mentioned HS Hospital Service S.P.A
Interventional Imaging Frequently Asked Questions (FAQ)
Where is Interventional Imaging's headquarters?
Interventional Imaging's headquarters is located at 1120 Chester, Suite 418, Cleveland.
What is Interventional Imaging's latest funding round?
Interventional Imaging's latest funding round is Other Investors.
Who are the investors of Interventional Imaging?
Investors of Interventional Imaging include Ohio TechAngels and Cleveland Heart.
Who are Interventional Imaging's competitors?
Competitors of Interventional Imaging include Novadaq Technologies, Oncoscope, CardioInsight Technologies, LipoScience, InfraReDx and 12 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Interventional Imaging to Competitors
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.
Bodyviz creates incredible 3D MRI, CT scan visualizations, unlocking medical imaging for virtually anyone including the practicing surgeon. This virtual reality (VR) visualization software is affordably priced, lightweight, simple to use, and runs on a typical PC.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
Green Imaging Technologies, Inc. (GIT) specializes in Magnetic Resonance Imaging (MRI) technology. Specifically GIT is a Systems Integrator of MRI technology for industrial solutions. MRI is perhaps best known for health and pharmaceutical purposes such as bone and tissue scanning. GIT will now turn the focus of this powerful technology on applications for industry beginning with the analysis of rock core plug samples taken from exploration wells in the petroleum sector. GIT has a new patent-pending Capillary Pressure Measurement process, GIT-CAPTM, that aims to provide more accurate data in 1/10 the time of the existing process that can take 3-4 weeks to perform.
Seno Medical is a medical imaging company. It develops and markets optoacoustic imaging technology for cancer diagnosis. It offers Imagio, a breast imaging system that combines laser optics and ultrasound technology to provide fused functional and anatomical breast imaging in real-time. It was founded in 2005 and is based in San Antonio, Texas.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
